ReviewAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
The DC1 conundrum: Do type I dendritic cells make or break allograft tolerance?
Review in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
True immunologic tolerance in solid organ transplantation (SOT) confers long-term allograft survival without the need for immunosuppression. Type 1 conventional dendritic cells (DC1s) have emerged as a cell type of particular interest in this context, owing to their unique transcriptional programming, specialization in cross-presentation, and indispensable role in maintaining self-tolerance. DC1s have traditionally been studied for their potent stimulatory role in tumor and viral immunology, whereas most dendritic cell (DC)-based tolerance research has historically focused on the monocyte-derived DC. A growing body of work highlights a duality of DC1s in both promoting and undermining allotolerance, as tissue microenvironment, antigen load, signal integration, and cellular crosstalk all contribute to a complex landscape of DC1 functionality. Recent advances in DC biology have enabled precise investigation of DC function and ontogeny, and accumulating evidence supports a subset-specific, tolerogenic role of DC1s in SOT. Moving beyond murine models, recent early phase clinical trials have demonstrated compelling patient safety and efficacy data for tolerogenic DC-based cellular therapy in SOT. In this review, we discuss the seemingly paradoxical discoveries of DC1s' supportive and antagonistic roles in allotolerance and consider emerging data highlighting their potential capabilities as a novel cellular therapy in SOT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.